Novo Nordisk's Pill, BMW's Struggle, Diageo Up

On this episode of Stock Movers:
- Novo Nordisk’s new Wegovy obesity pill fueled sales in the first quarter and the drugmaker said this year’s declines won’t be as bad as expected, a relief for investors.
- BMW’s carmaking returns fell in the first quarter as intense competition in China weighed on prices and deliveries in the world’s biggest auto market.
- Diageo’s sales unexpectedly rose in the latest quarter as growth in Africa and Latin America was enough to offset significant weakness in the US.

See omnystudio.com/listener for privacy information.